Skip to content

Effectiveness of radial shock wave treatment or tissue-specific plantar fascia-stretching in patients with chronic plantar heel pain

Effectiveness of radial shock wave treatment or tissue-specific plantar fascia-stretching in patients with chronic plantar heel pain: a randomised controlled observer-blinded trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11644582
Enrollment
250
Registered
2009-11-17
Start date
2007-07-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar fasciopathy Musculoskeletal Diseases Fibroblastic disorders

Interventions

Patients are randomly allocated to three sessions of radial shock wave treatment or to plantar fascia stretching: Group I: plantar fascia-specific stretching (PFSS), 3 x per day, for eight weeks Group

Sponsors

OrthoTrauma Evaluation Center (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. History of plantar fasciitis for more than 6 months 2. Numeric Rating Scale (NRS) score persistingly (at least 5 points for pain during the first few steps of walking in the morning) 3. Localised pain on palpation of the proximal plantar fascia 4. Be willing to abstain from any other treatments or medications during the treatment and follow-up period

Exclusion criteria

Exclusion criteria: 1. Less than 18 years of age 2. Receiving local injections less than 3 months prior to the randomisation visit 3. Receiving physical therapy less than 3 months prior to the randomisation visit 4. Receiving non-steroidal anti-imflammatory drugs (NSAIDs) for any chronic conditions whether or not related to plantar fasciitis prior to the randomisation visit 5. Receiving systemic therapeutic anticoagulants 6. Bilateral plantar fasciitis 7. History and/or physical findings of lower extremity dysfunction, local arthritis, generalised poly-arthritis, rheumatoid arthritis, ankylosing spondylitis, local arthrosis 8. Neurologic abnormality (changes of deep tendon reflexes, motor or sensory deficit) 9. Arthrosis of the foot or ankle, as confirmed by x-ray diagnosis (AP, lateral views) 10. Previous surgery of the foot 11. Participation in a Workman's Compensation Program or plans to apply for the Program 12. Thrombopathy, infection, tumour, diabetes mellitus, systemic lupus, severe cardiac disease or other severe systemic diseases 13. Pregnancy

Design outcomes

Primary

MeasureTime frame
Overall heel pain reduction measured by the percentage change of the VAS composite score 4 months after beginning of treatment compared with baseline, with last value carried forward (LVCF) replacement of missing values with the last recorded value.

Secondary

MeasureTime frame
1. 6-point Likert scale (fully recovered or significantly improved as success criteria) at 0, 4 and 12 months from baseline 2. Plantar fascia thickness measured before and 4 months and 15 months from baseline 3. Roles and Maudsley Score measured before and 4 months and 15 months from baseline 4. Number of patients achieving 80 points at at month 4, and at month 15 from baseline in the patient's function assessed using the validated 100-point AOFAS (American Orthopaedic Foot and Ankle Society) Ankle-Hindfoot-Score

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026